James S Blachly, MD

College

College of Medicine

Department/Division

Internal Medicine

Academic Title

Asst Professor

Research Program

Leukemia Research

Research Interest

Leukemia, Hairy Cell, Cancer, Leukemia, Lymphocytic, Chronic, B-Cell, Exanthema, hemorrhage, Infection, Melanoma, Carcinoma, Non-Small-Cell Lung, Colonic Cancer, Leukemia, Myeloid, Acute

Dr. Blachly's interest is in genomics and gene transcription in leukemia and its relevance in experimental therapeutics; namely, whether and how mutations and transcriptional attributes (including gene expression level, but also alternative splicing, alternative polyadenylation, non-protein coding RNAs, etc.) can be studied in the context of clinical trials to provide prognostic and predictive information relevant to novel anticancer therapies.

Education and Background

Office Location

B305 Starling Loving hall

320 W 10th Avenue, Columbus, OH 43210

614-685-5667

614-292-3312

james.blachly@osumc.edu

Publications

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.

Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, Grever MR

Leuk Lymphoma in press 09/18/2017
Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.

Duggan MC, Stiff AR, Bainazar M, Regan K, Olaverria Salavaggione GN, Maharry S, Blachly JS, Krischak M, Walker CJ, Latchana N, Tridandapani S, de la Chapelle A, Eisfeld AK, Carson WE

Proc Natl Acad Sci U S A in press 08/21/2017
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F

Leukemia 31 1547-1554 07/01/2017
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.

Eisfeld AK, Kohlschmidt J, Schwind S, Nicolet D, Blachly JS, Orwick S, Shah C, Bainazar M, Kroll KW, Walker CJ, Carroll AJ, Powell BL, Stone RM, Kolitz JE, Baer MR, de la Chapelle A, Mrózek K, Byrd JC, Bloomfield CD

Leukemia 31 1278-1285 06/01/2017
BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC

J Clin Oncol 35 1437-1443 05/01/2017
The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.

Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A, Blachly JS, Zhang X, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps TJ, Sampath D, Coombes KR, Hertlein EK

Oncotarget 8 25942-25954 04/18/2017
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.

Eisfeld AK, Mrózek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, Kroll KW, Blachly JS, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD

Leukemia in press 04/18/2017
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B

Blood 129 553-560 02/02/2017
Targeting BTK through microRNA in chronic lymphocytic leukemia.

Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, Woyach JA, Sampath D

Blood 128 3101-3112 12/29/2016
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.

Eisfeld AK, Kohlschmidt J, Mrózek K, Blachly JS, Nicolet D, Kroll K, Orwick S, Carroll AJ, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD

Leukemia 30 2254-2258 11/01/2016
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.

Bhatnagar B, Eisfeld AK, Nicolet D, Mrózek K, Blachly JS, Orwick S, Lucas DM, Kohlschmidt J, Blum W, Kolitz JE, Stone RM, Bloomfield CD, Byrd JC

Br J Haematol 175 226-236 10/01/2016
MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair.

Walker CJ, Miranda MA, Matthew J O, Blachly JS, Moyer CL, Ivanovich J, Krol0l KW, Eisfeld AK, Sapp CE, Mutch DG, Cohn DE, Bundschuh R, Goodfellow PJ, Walker CJ, Miranda MA, O'Hern MJ, Blachly JS, Moyer CL, Ivanovich J, Kroll KW, Eisfeld AK, Sapp CE, Mutch DG, Cohn DE, Bundschuh R, Goodfellow PJ

Hum Mutat 37 1004-12 10/01/2016
MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair.

Walker CJ, Miranda MA, Matthew J O, Blachly JS, Moyer CL, Ivanovich J, Krol0l KW, Eisfeld AK, Sapp CE, Mutch DG, Cohn DE, Bundschuh R, Goodfellow PJ, Walker CJ, Miranda MA, O'Hern MJ, Blachly JS, Moyer CL, Ivanovich J, Kroll KW, Eisfeld AK, Sapp CE, Mutch DG, Cohn DE, Bundschuh R, Goodfellow PJ

Hum Mutat 37 1004-12 10/01/2016
Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.

Maharry SE, Walker CJ, Liyanarachchi S, Mehta S, Patel M, Bainazar MA, Huang X, Lankenau MA, Hoag KW, Ranganathan P, Garzon R, Blachly JS, Guttridge DC, Bloomfield CD, de la Chapelle A, Eisfeld AK

Cancer Discov 6 1036-51 09/01/2016
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.

Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D, Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D

Clin Cancer Res 22 3537-49 07/15/2016
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.

Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D, Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D

Clin Cancer Res 22 3537-49 07/15/2016
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).

Bhatnagar B, Blachly JS, Kohlschmidt J, Eisfeld AK, Volinia S, Nicolet D, Carroll AJ, Block AM, Kolitz JE, Stone RM, Mrózek K, Byrd JC, Bloomfield CD, Bhatnagar B, Blachly JS, Kohlschmidt J, Eisfeld AK, Volinia S, Nicolet D, Carroll AJ, Block AW, Kolitz JE, Stone RM, Mrózek K, Byrd JC, Bloomfield CD

Leukemia 30 1586-9 07/01/2016
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).

Bhatnagar B, Blachly JS, Kohlschmidt J, Eisfeld AK, Volinia S, Nicolet D, Carroll AJ, Block AM, Kolitz JE, Stone RM, Mrózek K, Byrd JC, Bloomfield CD, Bhatnagar B, Blachly JS, Kohlschmidt J, Eisfeld AK, Volinia S, Nicolet D, Carroll AJ, Block AW, Kolitz JE, Stone RM, Mrózek K, Byrd JC, Bloomfield CD

Leukemia 30 1586-9 07/01/2016
MuCor: mutation aggregation and correlation.

Kroll KW, Eisfeld AK, Lozanski G, Bloomfield CD, Byrd JC, Blachly JS

Bioinformatics 32 1557-8 05/15/2016
Structural characterization of NRAS isoform 5.

Markowitz J, Mal TK, Yuan C, Courtney NB, Patel M, Stiff AR, Blachly J, Walker C, Eisfeld AK, de la Chapelle A, Carson WE 3rd

Protein Sci 25 1069-74 05/01/2016
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.

Blachly JS, Byrd JC, Grever M

Semin Oncol 43 265-73 04/01/2016
Ribosomal revelation.

Blachly JS

Blood 127 958-9 02/25/2016
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.

Maly J, Blachly JS

Curr Hematol Malig Rep 11 52-60 02/01/2016
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.

Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, Rassenti LZ, Kipps TJ, de la Chapelle A, Byrd JC

Proc Natl Acad Sci U S A 112 4322-7 04/07/2015
Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.

Blachly JS, Lozanski G, Lucas DM, Grever MR, Kendra K, Andritsos LA

J Natl Compr Canc Netw 13 9-13; quiz 13 01/01/2015
Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective.

Andritsos LA, Dunavin N, Lozanski G, Jones JA, Blachly JS, Lucas DM, Byrd JC, Kraut E, Grever MR

Haematologica 100 e18-20 01/01/2015
Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD

Proc Natl Acad Sci U S A 111 18679-84 12/30/2014

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

James S Blachly, MD

College

Department/Division

Academic Title

Research Program

Research Interest

Education and Background

Office Location

Publications

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.

Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.

BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Targeting BTK through microRNA in chronic lymphocytic leukemia.

Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.

MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair.

MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair.

Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.

HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.

HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).

MuCor: mutation aggregation and correlation.

Structural characterization of NRAS isoform 5.

Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.

Ribosomal revelation.

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.

Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.

Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

James S Blachly, MD

College

Department/Division

Academic Title

Research Program

Research Interest

Education and Background

Office Location

Publications

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication